NAT2 Genetic Testing
The NAT2 gen encodes the enzyme arylamine N-acetyltransferase 2. This enzyme metabolizes foreign compounds that enter the body as well as many therapeutic medications. Genetic mutation of the gene that produces the enzyme affects how a patient reacts to certain medications. Mutation of this gene can be hereditary but it is also often associated with some cancers and diseases that cause changes to the gene. Medications for tuberculosis, cardiovascular disease, and infection can all be affected by this enzyme.
Genetic Testing for Turberculosis Medication
Medications including hydralazine, isoniazid, and a variety of sulfonamides have been studied in their relation to the NAT2 gene. For this reason, patients who are about to begin treatment for cardiovascular disease, tuberculosis, or infection using one of these medications should consider the benefits of PGx testing. A simple PGx test can provide patients and providers with valuable information on potential risks for both side effects and medication inefficacy.
Pharmacogentic Testing for Isoniazid & Hydralazine
Patients with family histories of adverse effects from medications metabolized by the NAT2 enzyme should consider pharmacogentic testing. Patients who are about to begin treatment with Azulfidine® should consider this test to prevent issues with treatment. Pharmacogentic data can help patients and physicians predict and prevent a variety of issues and get to better patient outcomes quicker.
Order Phamacogenetic Testing For Azulfidine®
Azulfidine® is used to treat ulcerative colitis and rheumatoid arthritis. NAT2 genetic variation may affect how a patient metabolizes this medication. Patients who are beginning this treatment, have had issues with this treatment, or have a family history of issues with this treatment should consider learning more about pharmacogenetic testing. Patients should talk to their doctors about PGx testing and its benefits. Medical providers can order tests from TruGenX by contacting us.